|
Delenex fragments are best-in-class, clinically proven antibody fragments which significantly expand the therapeutic application range due to their unsurpassed qualities:
| 1. |
New administration routes (e.g. epicutaneous, intranasal) |
| 2. |
Local applications (e.g. skin, CNS, GIT, lung) |
| 3. |
Combat tissue-borne diseases (e.g. diseases affecting joints, skin, lung) |
| 4. |
Fight acute systemic medical conditions in which rapid and short intervention is of the essence (e.g. acute pain, intoxication, cytokine storm) |
Delenex provides stable, proprietary antibody fragments with low molecular weights ranging from about 25 kDa to 50 kDa. This small size, 1/6 and 1/3, respectively, of a full length immunoglobulin, as well as the PENTRA® fragments’ inherent features markedly expand the clinical application opportunities.
PENTRA® fragments are clearly differentiated from other fragments and non-antibody scaffolds:
| 1. |
Best-in-class biophysical parameters |
| 2. |
Proven in clinical trials |
| 3. |
Easy generation and handling |
| 4. |
Favourable, robust and proven GMP-production conditions in bacterial systems |
| 5. |
Commercialisation benefits |
| a. |
Independent, versatile antibody technology |
| b. |
No royalty stacking or other fees |
| c. |
Comprehensive patent/patent application portfolio established and maintained |
| d. |
Validated through the acquisition of ESBATech by Alcon Inc. in 2009 |
See also Intellectual Property
|
|
|
|
Further information
For more information, please check our latest presentations.
|
|